Wang, J., Wan, R., Zeng, S., Wu, L., Zhong, H., Wu, J., Wu, G., Duan, J., Wei, S., Zhang, Z., Wang, L., Li, J., Liu, J., Chen, Y., Wang, X., Hou, X., Wang, Q., Yu, H., Li, J. (2025). A phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 (anti-PD-L1 ADC) in patients with advanced/metastatic solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.3025